# Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

> **NCT04836156** · PHASE1,PHASE2 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 46 (estimated)

## Conditions studied

- HER2-negative Early Breast Cancer

## Interventions

- **DRUG:** neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
- **DRUG:** neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer

## Key facts

- **NCT ID:** NCT04836156
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-02
- **Primary completion:** 2022-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04836156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04836156, "Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04836156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*